Brief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
11/05/2026 10:16
May 11 (Reuters) - CanSino Biologics Inc 688185.SS: CHINA'S NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR TD5CP ADOLESCENT, ADULT Further company coverage: 688185.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025